{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-037736","form_type":"8-K","ticker":"AKTX","cik":"0001541157","company_name":"Akari Therapeutics Plc","filed_at":"2026-08-13T20:02:20+00:00","discovered_at":"2026-08-13T20:03:01.103681+00:00","generated_at":"2026-08-13T20:03:07.517018+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Akari Q2 net loss $4.8M; raises $8.6M; AKTX-101 on track for mid-2027 Phase 1","bullets":["Q2 2026 net loss $4.8M vs $1.9M YoY; R&D $2.1M up from $0.7M on IND-enabling work.","Cash $7.7M at June 30, 2026 vs $5.2M at Dec 31, 2025; raised $8.6M gross in quarter.","AKTX-101 progressing toward Phase 1 initiation planned for mid-2027; ASCO data on PH1 + KRAS inhibitor.","Research collaboration with Whitehawk Therapeutics on dual-payload ADCs combining PH1 with topoisomerase I payload."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-037736","json":"https://secwatch.observer/filing/0001493152-26-037736.json","markdown":"https://secwatch.observer/filing/0001493152-26-037736.md","text":"https://secwatch.observer/filing/0001493152-26-037736.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1541157/000149315226037736/0001493152-26-037736-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1541157/000149315226037736/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T20:03:07.517018+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}